Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK)
HKD 57.35
(4.08%)
HKD 57.35
(4.08%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.82 Billion CNY | -23.7% |
| 2022 | 10.25 Billion CNY | 121.08% |
| 2021 | 4.63 Billion CNY | 47.28% |
| 2020 | 3.14 Billion CNY | 28.04% |
| 2019 | 2.45 Billion CNY | 34.07% |
| 2018 | 1.83 Billion CNY | 28.94% |
| 2017 | 1.42 Billion CNY | 28.99% |
| 2016 | 1.1 Billion CNY | 32.82% |
| 2015 | 830.6 Million CNY | 15.97% |
| 2014 | 716.2 Million CNY | 31.96% |
| 2013 | 542.75 Million CNY | 27.89% |
| 2012 | 424.39 Million CNY | 4.61% |
| 2011 | 405.69 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.39 Billion CNY | -2.93% |
| 2024 Q2 | 1.29 Billion CNY | -7.31% |
| 2024 Q3 | 1.44 Billion CNY | 11.21% |
| 2023 Q2 | 2.37 Billion CNY | 5.49% |
| 2023 FY | 7.82 Billion CNY | -23.7% |
| 2023 Q4 | 1.44 Billion CNY | -18.13% |
| 2023 Q3 | 1.76 Billion CNY | -25.75% |
| 2023 Q1 | 2.24 Billion CNY | -7.97% |
| 2022 Q3 | 2.77 Billion CNY | -7.02% |
| 2022 FY | 10.25 Billion CNY | 121.08% |
| 2022 Q4 | 2.44 Billion CNY | -11.79% |
| 2022 Q2 | 2.97 Billion CNY | 44.52% |
| 2022 Q1 | 2.06 Billion CNY | 20.16% |
| 2021 Q1 | 777.18 Million CNY | -27.15% |
| 2021 Q4 | 1.71 Billion CNY | 47.56% |
| 2021 FY | 4.63 Billion CNY | 47.28% |
| 2021 Q3 | 1.16 Billion CNY | 18.29% |
| 2021 Q2 | 982.99 Million CNY | 26.48% |
| 2020 Q1 | 475.49 Million CNY | -33.73% |
| 2020 Q2 | 790.43 Million CNY | 66.23% |
| 2020 FY | 3.14 Billion CNY | 28.04% |
| 2020 Q3 | 816.91 Million CNY | 3.35% |
| 2020 Q4 | 1.06 Billion CNY | 30.59% |
| 2019 Q3 | 649.41 Million CNY | 5.33% |
| 2019 Q1 | 476.49 Million CNY | -24.36% |
| 2019 Q2 | 616.57 Million CNY | 29.4% |
| 2019 FY | 2.45 Billion CNY | 34.07% |
| 2019 Q4 | 717.5 Million CNY | 10.48% |
| 2018 Q1 | 363.65 Million CNY | -31.01% |
| 2018 FY | 1.83 Billion CNY | 28.94% |
| 2018 Q4 | 629.91 Million CNY | 40.82% |
| 2018 Q3 | 447.32 Million CNY | 13.54% |
| 2018 Q2 | 393.98 Million CNY | 8.34% |
| 2017 Q2 | 261.37 Million CNY | -9.9% |
| 2017 FY | 1.42 Billion CNY | 28.99% |
| 2017 Q4 | 527.09 Million CNY | 53.02% |
| 2017 Q3 | 344.46 Million CNY | 31.79% |
| 2017 Q1 | 290.09 Million CNY | -8.6% |
| 2016 Q1 | 186.68 Million CNY | -39.92% |
| 2016 FY | 1.1 Billion CNY | 32.82% |
| 2016 Q4 | 317.39 Million CNY | 0.65% |
| 2016 Q3 | 315.32 Million CNY | 11.11% |
| 2016 Q2 | 283.79 Million CNY | 52.02% |
| 2015 Q3 | 149.06 Million CNY | 0.0% |
| 2015 Q4 | 310.71 Million CNY | 108.45% |
| 2015 FY | 830.6 Million CNY | 15.97% |
| 2014 FY | 716.2 Million CNY | 31.96% |
| 2013 FY | 542.75 Million CNY | 27.89% |
| 2012 FY | 424.39 Million CNY | 4.61% |
| 2011 FY | 405.69 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 484.71 Million HKD | -1514.38% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.32 Billion HKD | -47.015% |